Stay updated on Cabozantinib Reverses Carfilzomib Resistance in Myeloma Clinical Trial

Sign up to get notified when there's something new on the Cabozantinib Reverses Carfilzomib Resistance in Myeloma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Cabozantinib Reverses Carfilzomib Resistance in Myeloma Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    Revision history updated: added v3.5.0 and removed v3.4.3.
    Difference
    0.1%
    Check dated 2026-03-19T04:28:35.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    Revision label updated from v3.4.2 to v3.4.3.
    Difference
    0.1%
    Check dated 2026-03-11T23:44:49.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    23 days ago
    No Change Detected
  5. Check
    38 days ago
    Change Detected
    Summary
    A new site revision tag 'Revision: v3.4.2' is shown, while the older funding-status notice and the earlier 'Revision: v3.4.1' text have been removed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-11T11:37:32.000Z thumbnail image
  6. Check
    45 days ago
    Change Detected
    Summary
    A government funding/operating status notice was added and the site revision updated from v3.4.0 to v3.4.1; this change does not affect study content or results. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-04T10:28:40.000Z thumbnail image
  7. Check
    52 days ago
    Change Detected
    Summary
    The page now displays a glossary by default, shows a 'Last Update Submitted that Met QC Criteria' status, and includes a 'No FEAR Act Data' note along with a revision banner 'Revision: v3.4.0'.
    Difference
    0.2%
    Check dated 2026-01-28T06:22:47.000Z thumbnail image
  8. Check
    66 days ago
    Change Detected
    Summary
    Revision metadata updated from v3.3.3 to v3.3.4; no study information, eligibility criteria, or results appear to be modified. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-14T02:13:13.000Z thumbnail image

Stay in the know with updates to Cabozantinib Reverses Carfilzomib Resistance in Myeloma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Cabozantinib Reverses Carfilzomib Resistance in Myeloma Clinical Trial page.